دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment
Dominik Menges a,*, Henock G. Yebyo a , Sergio Sivec-Muniz a , Sarah R. Haile a , Michaela C. Barbier b , Yuki Tomonaga a , Matthias Schwenkglenks a,b , Milo A. Puhan
doi : 10.1016/j.euo.2022.04.007
Volume 5, Issue 6, December 2022, Pages 605-616
Multiple treatments for metastatic, hormone-sensitive prostate cancer (mHSPC) are available, but their effects on health-related quality of life (HRQoL) and benefit-harm balance remain unclear.
Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and Metaregression
Michael Baboudjian a,b,c,d,*,y, Alberto Breda c,y, Pawel Rajwa e,f , Andrea Gallioli c , Bastien Gondran-Tellier b , Francesco Sanguedolce c,l , Paolo Verri c , Pietro Diana c , Angelo Territo c , Cyrille Bastide a , Daniel E. Spratt g , Stacy Loeb h , Jeffrey J. Tosoian i , Michael S. Leapman j , Joan Palou c , Guillaume Ploussard
doi : 10.1016/j.euo.2022.07.004
Volume 5, Issue 6, December 2022, Pages 617-627
Active surveillance (AS) is increasingly selected among patients with localized, intermediate-risk (IR) prostate cancer (PCa). However, the safety and optimal candidate selection for those with IR PCa remain uncertain.
Epidemiology, Screening, and Prevention of Bladder Cancer
Niyati Lobo a , Luca Afferi b , Marco Moschini c , Hugh Mostafid a , Sima Porten d , Sarah P. Psutka e , Shilpa Gupta f , Angela B. Smith g , Stephen B. Williams h , Yair Lotan
doi : 10.1016/j.euo.2022.10.003
Volume 5, Issue 6, December 2022, Pages 628-639
Bladder cancer (BC) represents a significant health problem due to the potential morbidity and mortality associated with disease burden, which has remained largely unaltered over time.
Three-dimensional Model–assisted Minimally Invasive Partial Nephrectomy: A Systematic Review with Meta-analysis of Comparative Studies
Federico Piramide a,b,y,*, Karl-Friedrich Kowalewski c,d,y, Giovanni Cacciamani d,e , Ines Rivero Belenchon d,f , Mark Taratkin d,g , Umberto Carbonara h,i , Michele Marchioni h,j , Ruben De Groote b,k,l , Sophie Knipper b,m , Angela Pecoraro h,n , Filippo Turri b,o , Paolo Dell’Oglio b,p , Stefano Puliatti d,q , Daniele Amparore a,h , Gabriele Volpi a , Riccardo Campi h,r , Alessandro Larcher b,s , Alex Mottrie k,l , Alberto Breda t , Andrea Minervini u,v , Ahmed Ghazi w , Prokar Dasgupta x , Ali Gozen y , Riccardo Autorino z , Cristian Fiori a , Michele Di Dio aa , Juan Gomez Rivas d,bb , Francesco Porpiglia a,à , Enrico Checcucci d,cc,à , on behalf of the European Association of Urology Young Academic Urologists and the European Section of Uro-Technology
doi : 10.1016/j.euo.2022.09.003
Volume 5, Issue 6, December 2022, Pages 640-650
Use of three-dimensional (3D) guidance for nephron-sparing surgery (NSS) has increased in popularity, especially for laparoscopic and robotic approaches. Different 3D visualization modalities have been developed as promising new tools for surgical planning and intraoperative navigation.
A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer—Data from the International Multicenter Prospective PRIAS Study
Henk Benjamin Luiting a,*, Sebastiaan Remmers a , Egbert R. Boeve � b , Riccardo Valdagni c , Peter K. Chiu d , Axel Semjonow e , Viktor Berge f , Karl H. Tully g , Antti S. Rannikko h , Fre �de �ric Staerman i , Monique J. Roobol
doi : 10.1016/j.euo.2022.03.007
Volume 5, Issue 6, December 2022, Pages 651-658
There is ongoing discussion whether a multivariable approach including magnetic resonance imaging (MRI) can safely prevent unnecessary protocol-advised repeat biopsy during active surveillance (AS).
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer
Marı �a Dolores Fenor de la Maza a,b , Khobe Chandran a,b , Jan Rekowski a , Irene M. Shui c , Bora Gurel a , Emily Cross a , Suzanne Carreira a , Wei Yuan a , Daniel Westaby a,b , Susana Miranda a,b , Ana Ferreira a , George Seed a , Mateus Crespo a , Ines Figueiredo a , Claudia Bertan a , Veronica Gil a , Ruth Riisnaes a , Adam Sharp a,b , Daniel Nava Rodrigues d , Pasquale Rescigno e , Nina Tunariu a,b , Xiao Qiao Liu c , Razvan Cristescu c , Charles Schloss c , Christina Yap a , Johann S. de Bono
doi : 10.1016/j.euo.2022.04.004
Volume 5, Issue 6, December 2022, Pages 659-667
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease in which molecular stratification is needed to improve clinical outcomes. The identification of predictive biomarkers can have a major impact on the care of these patients, but the availability of metastatic tissue samples for research in this setting is limited.
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography–based Lymph Node Atlas for Salvage Radiotherapy in Patients with Recurrent Prostate Cancer: A Validation of the New NRG Oncology 2020 guideline
Marco M.E. Vogel a,*, Mathias Du ̈sberg a , Lucia Sto ̈hrer a , Sabrina Dewes a , Eva K. Sage a , Kai J. Borm a , Ju ̈rgen E. Gschwend b , Matthias Eiber c , Stephanie E. Combs a,d,e , Kilian Schiller
doi : 10.1016/j.euo.2022.09.006
Volume 5, Issue 6, December 2022, Pages 668-676
Approximately 20–40% of patients with prostate cancer (PC) who undergo radical prostatectomy (RP) experience relapse, with the majority of these cases developing pelvic lymph node (LN) metastases.
Somatic Features of Response and Relapse in Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy
Jack V.W. Bacon a,y, David C. Mu ̈ller b,c,y, Elie Ritch a , Matti Annala a,d , Sarah G. Dugas b,c , Cameron Herberts a , Gillian Vandekerkhove a , Helge Seifert c , Tobias Zellweger e , Peter C. Black a , Lukas Bubendorf b , Alexander W. Wyatt a,f,*, Cyrill A. Rentsch
doi : 10.1016/j.euo.2021.11.002
Volume 5, Issue 6, December 2022, Pages 677-686
High-risk non–muscle-invasive bladder cancer (NMIBC) is treated with bacillus Calmette-Guérin (BCG), but relapse is common. Improvement of patient outcomes requires better understanding of links between BCG resistance and genomic driver alterations.
Predicting Oncologic Outcomes in Small Renal Tumors
Payal Kapur a,b,c,*,1 , Hua Zhong a,d,1 , Ellen Araj a , Alana Christie c , Qi Cai a , David Kim a , Jeffrey Miyata c,e , Vanina T. Tcheuyap c,e , Olivia Brandenburg c,e , Deyssy Carrillo c,e , Ivan Pedrosa b,c,f , James Brugarolas c,e,*, Jeffrey A. Cadeddu
doi : 10.1016/j.euo.2022.08.003
Volume 5, Issue 6, December 2022, Pages 687-694
Most patients diagnosed with renal cancer today present with small renal masses (SRMs). Although these patients have a low risk of dying from their disease and many are followed with active surveillance protocols, a small subset of renal cell carcinomas (RCCs) behave aggressively. Knowledge regarding features of aggressive behavior would enable better adoption of active surveillance strategies among these patients.
Stereotactic Ablative Radiation for Systemic Therapy–naïve Oligometastatic Kidney Cancer
Raquibul Hannan a,b,*, Michael Christensen a , Alana Christie b , Aurelie Garant a,b , Ivan Pedrosa b,d , Liliana Robles a , Samantha Mannala a , Chiachien Wang a , Hans Hammers b,c , Waddah Arafat b,c , Kevin Courtney b,c , Isaac A. Bowman b,c , David Sher a , Chul Ahn b , Suzanne Cole b,c , Hak Choy a , Robert Timmerman a,b,*, James Brugarolas
doi : 10.1016/j.euo.2022.06.008
Volume 5, Issue 6, December 2022, Pages 695-703
Evidence-based guidelines for the management of systemic therapy–naïve oligometastatic renal cell carcinoma (RCC) are lacking.
Sentinel Node Identification with Hybrid Tracer-guided and Conventional Dynamic Sentinel Node Biopsy in Penile Cancer: A Prospective Study in 130 Patients from the Two National Referral Centres in Sweden
Christian Torbrand a,b,*, A ̊ sa Warnolf b,c , Dominik Glombik d , Sabina Davidsson d , Jessica Carlsson d , Gediminas Baseckas b,c , Ulf Ha ̊ kansson e , Elin Tra ̈ga ̊ rdh f,g , Ha ̊ kan Geijer h , Fredrik Liedberg b,c , Peter Kirrander
doi : 10.1016/j.euo.2022.09.004
Volume 5, Issue 6, December 2022, Pages 704-711
Studies suggest that a hybrid indocyanine green (ICG)-99mTc-nanocolloid tracer improves sentinel node (SN) identification compared to conventional dynamic sentinel node biopsy (DSNB).
Will Dynamic Sentinel Lymph Node Biopsy Surpass Inguinal Lymph Node Dissection in High-risk Node-negative Penile Cancer?
Taylor Peak, Logan Zemp, Philippe E. Spiess
doi : 10.1016/j.euo.2022.10.005
Volume 5, Issue 6, December 2022, Pages 712-713
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells
Jonathan Chou a,b,*,y, Kai Trepka a,b,c,d,y, Martin Sjo ̈stro ̈m b,c , Emily A. Egusa b,c , Carissa E. Chu b,e , Jun Zhu b,c , Emily Chan b,f , Ewan A. Gibb g , Michelle L. Badura b,c , Alberto Contreras-Sanz h , Bradley A. Stohr b,f , Maxwell V. Meng b,e , Raj S. Pruthi b,e , Yair Lotan i , Peter C. Black h , Sima P. Porten b,e , Vadim S. Koshkin a,b , Terence W. Friedlander a,b , Felix Y. Feng
doi : 10.1016/j.euo.2021.11.005
Volume 5, Issue 6, December 2022, Pages 714-718
Sacituzumab govitecan (SG) is an antibody-drug conjugate (ADC) targeting TROP2, which has recently been approved for treatment-refractory metastatic urothelial cancer (UC).
Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma
Chris Labaki, Ziad Bakouny, Guru Sonpavde, Toni K. Choueiri, Eliezer M. Van Allen
doi : 10.1016/j.euo.2022.01.004
Volume 5, Issue 6, December 2022, Pages 719-721
Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer
Luca Afferi a,*, Chiara Lonati a,b , Francesco Montorsi c , Alberto Briganti c , Andrea Necchi d , Andrea Mari e , Andrea Minervini e , Riccardo Tellini e , Riccardo Campi e , Gerald Bastian Schulz f,g , Peter C. Black g , Ettore di Trapani h , Ottavio de Cobelli h,i , R. Jeffrey Karnes j , Mohamed Ahmed j , M. Carmen Mir k , Maria Asuncion Algarra k , Michael Rink l , Stefania Zamboni b , Francesca Mondini b , Claudio Simeone b , Alessandro Antonelli m , Alessandro Tafuri m , Wojciech Krajewski n , Bartosz MaA ̃A ̃lkiewicz n , Evanguelos Xylinas o , Francesco Soria p , Rafael Sanchez Salas q , Amandeep Arora q , Xavier Cathelineau q , Kees Hendricksen r , Maida Ammiwala r , Marco Borghesi s , Francesco Chierigo s , Jeremy Yuen-Chun Teoh t , Agostino Mattei a , Simone Albisinni u , Florian Roghmann v , Mathieu Roumiguie � w , Anne Sophie Bajeot w , Elisabeth Maier x , Atiqullah Aziz x , Rodolfo Hurle y , Roberto Contieri y , Benjamin Pradere ac , Roberto Carando a,ah,ai , Cedric Poyet z , Mario Alvarez-Maestro aa,ab , David D’Andrea ac , Shahrokh F. Shariat ac,ad,ae,af,ag , Marco Moschini a,c , on behalf of the European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group
doi : 10.1016/j.euo.2022.04.001
Volume 5, Issue 6, December 2022, Pages 722-725
A trend towards greater benefit from adjuvant chemotherapy (ACT) in pN+ bladder cancer (BCa) has been observed in multiple randomized controlled trials.
Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities
M. Carmen Mir a , Riccardo Campi b,c , Yohann Loriot d , Javier Puente e , Gianluca Giannarini f , Andrea Necchi g,h , Morgan Roupreˆt i, *, on behalf of the EAU Section of Oncological Urology (ESOU) Board
doi : 10.1016/j.euo.2021.04.004
Volume 5, Issue 6, December 2022, Pages 726-731
We describe the case of a 71-yr-old woman with locally advanced muscle-invasive bladder cancer and stage III chronic kidney disease due to an obstructed nonfunctional left kidney.
Quality Goal for Salvage Treatment for Patients with Prostate Cancer at Prostate-specific Antigen Relapse
Rie von Eyben a Manuela Andrea Hoffmann b,c Daniel S. Kapp a Cigdem Soydal d Christian Uprimny e Irene Virgolini e Murat Tuncel
doi : 10.1016/j.euo.2022.01.005
Volume 5, Issue 6, December 2022, Pages 732-733
